Plain-English translation of NCT06285279 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses your own immune cells that have been specially modified in the laboratory to target and control your autoimmune kidney disease. The modified cells are designed to reduce the overactive immune response that is damaging your kidneys. Researchers want to see if this treatment is safe and effective for people whose kidney disease has not improved with standard medications.
Many people with autoimmune kidney diseases do not respond well to standard treatments or their disease comes back after initial improvement. This medication represents a new approach that may help people whose kidneys continue to be damaged despite current therapies.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure to collect your white blood cells, which will then be modified in the laboratory over several weeks. Before receiving the treatment, you will receive chemotherapy medications for three days to prepare your immune system. Then you will receive a single infusion of the modified cells over about 30 minutes. After that, you will be followed closely in the clinic for at least 2 years with regular blood tests, urine tests, and imaging to see how you are responding and to monitor for any side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China